[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342626-105":3,"doc-detail-342626-en":81,"detail-sidebar-cat-0-en-105":99},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","high-intensity-focused-ultrasound-with-visually-directed-power-adjustment-for-focal-treatment-of-localized-prostate-cancer-systematic-review-and-meta-analysis","High-intensity focused ultrasound with visually directed power adjustment for focal treatment of localized prostate cancer - systematic review and meta-analysis","","Visually directed high-intensity focused ultrasound (HIFU) is assessed for focal treatment of localized prostate cancer to quantify patient outcomes and complications. A systematic review synthesized cancer-control endpoints and adverse events from observational studies, using random-effects meta-analysis. Eight studies including 1,819 men (median follow-up 24 months) reported PSA nadir, biopsy findings, salvage treatment rates, and complication frequencies such as erectile dysfunction, urinary retention, infection, incontinence, and bowel injury. Findings suggest relatively low medium-term complication risk with acceptable cancer control, while comparative long-term evidence remains limited.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/high-intensity-focused-ultrasound-with-visually-directed-power-adjustment-for-focal-treatment-of-localized-prostate-cancer-systematic-review-and-meta-analysis/342626/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/high-intensity-focused-ultrasound-with-visually-directed-power-adjustment-for-focal-treatment-of-localized-prostate-cancer-systematic-review-and-meta-analysis/342626.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the systematic review and meta-analysis?","Question",{"text":63,"@type":64},"To characterize patient outcomes following visually directed high-intensity focused ultrasound (HIFU) for focal treatment of localized prostate cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which studies and patients were included in the analysis?",{"text":68,"@type":64},"The review included randomized trials and observational studies of visually directed HIFU for focal treatment, excluding algorithm-directed protocols, whole-gland HIFU, salvage HIFU, and several other study types or insufficient sample sizes.",{"name":70,"@type":61,"acceptedAnswer":71},"What complication and cancer-control outcomes were reported?",{"text":72,"@type":64},"Across eight observational studies (1,819 patients), the analysis reported PSA nadir timing, clinically significant positive biopsy rates, salvage treatment rates, and complication rates including erectile dysfunction, urinary retention, urinary tract infection, urinary incontinence, and bowel injury.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342626,1790535830,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d",7,"World Journal of Urology (2024) 42:175  \n[https://doi.org/10.1007/s00345-024-04840-6](https://doi.org/10.1007/s00345-024-04840-6)  \nHigh‑intensity focused ultrasound with visually directed power adjustment for focal treatment of localized prostate cancer: systematic review and meta‑analysis  \nSamuel J. Peretsman1 · Mark Emberton2 · Neil Fleshner3 · Sunao Shoji4 · Clinton D. Bahler5 ·  \nLarry E. Miller6  \nReceived: 23 September 2023 / Accepted: 16 January 2024 / Published online: 20 March 2024 © The Author(s) 2024  \nAbstract  \nPurpose To characterize patient outcomes following visually directed high-intensity focused ultrasound (HIFU) for focal treatment of localized prostate cancer.  \nMethods We performed a systematic review of cancer-control outcomes and complication rates among men with localized prostate cancer treated with visually directed focal HIFU. Study outcomes were calculated using a random-effects metaanalysis model.  \nResults A total of 8 observational studies with 1,819 patients (median age 67 years; prostate-specific antigen 7.1 mg/ml; prostate volume 36 ml) followed over a median of 24 months were included. The mean prostate-specific antigen nadir following visually directed focal HIFU was 2.2 ng/ml (95% CI 0.9–3.5 ng/ml), achieved after a median of 6 months post-treatment. A clinically significant positive biopsy was identified in 19.8%(95% CI 12.4–28.3%) of cases. Salvage treatment rates were 16.2%(95% CI 9.7–23.8%) for focal-or whole-gland treatment, and 8.6%(95% CI 6.1–11.5%) for whole-gland treatment. Complication rates were 16.7%(95% CI 9.9–24.6%) for de novo erectile dysfunction, 6.2%(95% CI 0.0–19.0%) for urinary retention, 3.0%(95% CI 2.1–3.9%) for urinary tract infection, 1.9%(95% CI 0.1–5.3%) for urinary incontinence, and 0.1%(95% CI 0.0–1.4%) for bowel injury.  \nConclusion Limited evidence from eight observational studies demonstrated that visually directed HIFU for focal treatment of localized prostate cancer was associated with a relatively low risk of complications and acceptable cancer control over medium-term follow-up. Comparative, long-term safety and effectiveness results with visually directed focal HIFU are lacking.  \nKeywords Focal therapy · HIFU · High-intensity focused ultrasound · Meta-analysis · Prostate cancer · Systematic review  \n* Larry E. Miller [larry@millerscientific.com](larry@millerscientific.com)[ ](larry@millerscientific.com)Samuel J. Peretsman [samuelperetsman@sonablate.com](samuelperetsman@sonablate.com)[ ](samuelperetsman@sonablate.com)Mark Emberton [m.emberton@ucl.ac.uk](m.emberton@ucl.ac.uk)  \nNeil Fleshner  \n[Neil.fleshner@uhn.ca](Neil.fleshner@uhn.ca)  \nSunao Shoji  \n[sunashoj@mail.goo.ne.jp](sunashoj@mail.goo.ne.jp)  \nClinton D. Bahler  \n[cdbahler@iupui.edu](cdbahler@iupui.edu)  \n1 Charlotte, NC, USA  \n2 Interventional Oncology, Division of Surgery and Interventional Science, University College London, London, UK  \n3 Department of Surgical Oncology Urology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada  \n4 Department of Urology, Tokai University School of Medicine, Isehara, Japan  \n5 Department of Urology, Indiana University, Indianapolis, IN, USA  \n6 Miller Scientific, 3101 Browns Mill Road, Ste 6, \\#311, Johnson City, TN 37604, USA  \nIntroduction  \nOver 1.4 million men worldwide receive a prostate cancer (PCa) diagnosis each year [1], and 1 in 8 men receive this diagnosis during their lifetime [2] . Approximately 87% of these cancers are localized to the prostate without the involvement of nearby organs [3] . While whole-gland tumors are typically treated with radical radiotherapy or prostatectomy, localized tumors may be treated with organsparing focal therapies intended to minimize side effects while bridging active surveillance and radical treatment in low-and intermediate-risk patients. High-intensity focused ultrasound (HIFU) is a therapy for PCa that targets energy atthe index lesion, resulting in coagulating necrosis of maligna","cbCailspEPFGHgRM","https://ap.wps.com/l/cbCailspEPFGHgRM","pdf",565641,9,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Treatment rationale for localized prostate cancer\n## HIFU treatment approaches: algorithm-directed vs visually directed\n# Methods\n## PRISMA framework and review registration\n## Study eligibility criteria","[{\"question\":\"What is the main purpose of the systematic review and meta-analysis?\",\"answer\":\"To characterize patient outcomes following visually directed high-intensity focused ultrasound (HIFU) for focal treatment of localized prostate cancer.\"},{\"question\":\"Which studies and patients were included in the analysis?\",\"answer\":\"The review included randomized trials and observational studies of visually directed HIFU for focal treatment, excluding algorithm-directed protocols, whole-gland HIFU, salvage HIFU, and several other study types or insufficient sample sizes.\"},{\"question\":\"What complication and cancer-control outcomes were reported?\",\"answer\":\"Across eight observational studies (1,819 patients), the analysis reported PSA nadir timing, clinically significant positive biopsy rates, salvage treatment rates, and complication rates including erectile dysfunction, urinary retention, urinary tract infection, urinary incontinence, and bowel injury.\"}]","High-intensity focused ultrasound with visually directed power adjustment for focal treatment of localized prostate cancer - systematic review and meta-analysis | PDF",1790047445,23,{"code":4,"msg":82,"data":100},[101,105,109,113,118,123,126,131,135,138,142],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":110,"show_sort_weight":111,"slug":112},"Exam",70,"exam",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},5,"Comic",60,"comic",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},6,"Technology",50,"technology",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":124,"slug":125},40,"healthcare",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":129,"slug":130},8,"Research & Report",30,"research-report",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},"Religion & Spirituality",20,"religion-spirituality",{"id":133,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":133,"slug":137},"World Cup","world-cup",{"id":139,"doc_module":4,"doc_module_name":25,"category_name":140,"show_sort_weight":139,"slug":141},10,"Lifestyle","lifestyle",{"id":143,"doc_module":4,"doc_module_name":25,"category_name":144,"show_sort_weight":114,"slug":145},19,"General","general"]